Zacks Research upgraded shares of Salzgitter (OTCMKTS:SZGPY – Free Report) from a strong sell rating to a hold rating in a research note published on Monday,Zacks.com reports.
Several other equities research analysts have also recently weighed in on the company. BNP Paribas upgraded Salzgitter to an “outperform” rating in a report on Friday, October 3rd. DZ Bank cut Salzgitter from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Salzgitter presently has a consensus rating of “Hold”.
View Our Latest Stock Analysis on SZGPY
Salzgitter Stock Down 10.4%
Salzgitter (OTCMKTS:SZGPY – Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The basic materials company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.16). Salzgitter had a negative net margin of 4.45% and a negative return on equity of 9.40%. The business had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.33 billion. Equities analysts anticipate that Salzgitter will post -0.68 EPS for the current fiscal year.
Salzgitter Company Profile
Salzgitter AG, together with its subsidiaries, engages in steel and technology businesses worldwide. It operates through four segments: Steel Production, Steel Processing, Trading, and Technology. The Steel Production segment manufactures steel and special steels, such as hot-rolled wide strip, steel sheet, sections, tailored blanks, as well as scrap trading.
Further Reading
- Five stocks we like better than Salzgitter
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- How Investors Can Find the Best Cheap Dividend Stocks
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Ride Out The Recession With These Dividend Kings
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Salzgitter Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salzgitter and related companies with MarketBeat.com's FREE daily email newsletter.